Technology
Health
Biotechnology

Xenetic

$0.7351
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0085 (1.13%) Today
-$0.0249 (-3.28%) After Hours

Why Robinhood?

You can buy or sell Xenetic and other stocks, options, ETFs, and crypto commission-free!

About

Xenetic Biosciences, Inc. engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. Read More It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Employees
4
Headquarters
Framingham, Massachusetts
Founded
2011
Market Cap
7.85M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
258.22K
High Today
$0.77
Low Today
$0.7201
Open Price
$0.76
Volume
25.84K
52 Week High
$8.95
52 Week Low
$0.7101

Collections

Technology
Health
Biotechnology
Research And Development
Therapy
Cancer Prevention
US
North America

News

Yahoo FinanceMay 13

Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update

Company on track to close acquisition of novel XCART platform technology Entry into CAR T space positions company to drive significant momentum over the course of 2019 advancing XCART platform technology XCART initially being developed to target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non-Hodgkin Lymphoma of over $5 billion annually 1 FRAMINGHAM, MA / ACCESSWIRE / May 13, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the ...

256
Yahoo FinanceMay 2

Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.

Represents key appointment to bolster scientific and oncology expertise as Company prepares to advance XCART platform technology Internationally renowned expert in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, both with autologous and allogeneic stem cell transplantations Pioneer in developing specific donor-derived immune cells FRAMINGHAM, MA / ACCESSWIRE / May 2, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clini...

142

Earnings

-$0.54
-$0.19
$0.17
$0.52
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.54 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.